These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20877639)

  • 1. Heightened vulnerability to MDR-TB epidemics after controlling drug-susceptible TB.
    Bishai JD; Bishai WR; Bishai DM
    PLoS One; 2010 Sep; 5(9):e12843. PubMed ID: 20877639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.
    van Maaren PJ
    Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains.
    McBryde ES; Meehan MT; Doan TN; Ragonnet R; Marais BJ; Guernier V; Trauer JM
    Int J Infect Dis; 2017 Mar; 56():14-20. PubMed ID: 28163165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia.
    Mekonnen F; Tessema B; Moges F; Gelaw A; Eshetie S; Kumera G
    BMC Infect Dis; 2015 Oct; 15():461. PubMed ID: 26503269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease control implications of India's changing multi-drug resistant tuberculosis epidemic.
    Suen SC; Bendavid E; Goldhaber-Fiebert JD
    PLoS One; 2014; 9(3):e89822. PubMed ID: 24608234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa.
    Cox HS; McDermid C; Azevedo V; Muller O; Coetzee D; Simpson J; Barnard M; Coetzee G; van Cutsem G; Goemaere E
    PLoS One; 2010 Nov; 5(11):e13901. PubMed ID: 21085569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the transmission risk of multidrug-resistant Mycobacterium tuberculosis epidemics in regions of Taiwan.
    Liao CM; Lin YJ
    Int J Infect Dis; 2012 Oct; 16(10):e739-47. PubMed ID: 22818291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
    Chang KC; Yew WW
    Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
    Juma SP; Maro A; Pholwat S; Mpagama SG; Gratz J; Liyoyo A; Houpt ER; Kibiki GS; Mmbaga BT; Heysell SK
    BMC Infect Dis; 2019 Feb; 19(1):129. PubMed ID: 30732572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multidrug-resistant tuberculosis: challenges of a global emergence].
    Comolet T
    Bull Soc Pathol Exot; 2015 Oct; 108(4):290-8. PubMed ID: 26289547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome of multidrug-resistant tuberculosis in Japan - the first cross-sectional study of Japan tuberculosis surveillance data.
    Kawatsu L; Uchimura K; Izumi K; Ohkado A; Yoshiyama T
    BMC Infect Dis; 2018 Aug; 18(1):445. PubMed ID: 30170549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-drug resistant tuberculosis burden and risk factors: an update.
    Marahatta SB
    Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
    Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
    Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
    Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
    Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for halting the rise of multidrug resistant TB epidemics: assessing the effect of early case detection and isolation.
    Espindola AL; Varughese M; Laskowski M; Shoukat A; Heffernan JM; Moghadas SM
    Int Health; 2017 Mar; 9(2):80-90. PubMed ID: 28338827
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.